Latest News

October 26, 2022

Press Release: NCI-MATCH cancer trial finds a promising signal for the AKT inhibitor ipatasertib

October 21, 2022

Press Release: Head and neck cancer researchers demonstrate the capability of a deep learning algorithm in the post-surgery setting to assess the stage of disease more accurately using standard CT scans

October 20, 2022

Press Release: ECOG-ACRIN taps the University of Pennsylvania’s Selina Luger to lead its Leukemia Committee

October 13, 2022

The September/October 2022 News from ECOG-ACRIN blog is now available

October 4, 2022

DREAMseq trial clarifies immunotherapy, targeted treatment order for patients with BRAF-mutant metastatic melanoma

September 30, 2022

Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy

September 28, 2022

Immunotherapy before targeted therapy improves survival in advanced melanoma, according to the DREAMseq trial

September 27, 2022

Media Advisory: Journal of Clinical Oncology publishes outcomes from the practice-changing DREAMseq trial in patients with advanced melanoma

September 26, 2022

The Fall 2022 advocacy blog Considering Clinical Trials is now available


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
43

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group